Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Testosterone prescribing and persistence among adult females: a new-user cohort study.

Created on 10 Nov 2026

Authors

Sarah C J Jorgensen, David L McClure

Published in

The Journal of clinical endocrinology and metabolism. Nov 10, 2026. Epub Nov 10, 2026.

Abstract

Testosterone use among females has risen recently, partly fueled by consumer-directed marketing for a wide range of unsupported indications. Hypoactive sexual desire disorder (HSDD) in postmenopausal females remains the only evidence-based indication.
To describe characteristics of females initiating testosterone, indications, temporal trends, serum concentration monitoring, and duration of therapy.
Retrospective new-user cohort study using TriNetX de-identified electronic health record (EHR) data. Adult females newly prescribed testosterone 2016-2024 were included. Patients with gender incongruence were excluded.
In total, 10,185 females were included; median age 52 (42-59) years. Cardiac disease, ≥1 psychiatric diagnosis, and a history of breast or gynecological cancer were documented in 20%, 36%, 3.1% and 2.8%, respectively. HSDD was documented in 17%. The annual percent change in new testosterone users was 7.5% (95% CI, -1.0-10%) 2016-2022 and 22% (95% CI, 12-29%) 2022-2024. The prevalence of testosterone serum concentration monitoring was 16% at baseline and 10% at 60-180 days. Concentrations >70ng/dL were documented in 38% of those tested at follow-up. 59% received a single testosterone prescription; among those with ≥2 prescriptions, the median time to discontinuation was 19.3 months (95% CI, 18.8-20.0).
New testosterone use among females increased over the study, was most often prescribed without a documented HSDD diagnosis, many had pre-existing conditions excluded from clinical trials, monitoring reported in the EHR was low, and concentrations >70 ng/dL were documented in 38% of those tested. Among those who continued therapy, a substantial proportion persisted beyond 24 months for which limited safety data are available.

PMID:
43006835
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement